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Department of Chemical and Biological Engineering, Princeton University, New JerseyABSTRACT HIV-1 cell entry is initiated by the interaction of the viral envelope glycoprotein gp120 with CD4, and chemokine
coreceptors CXCR4 and CCR5. The molecular recognition of CXCR4 or CCR5 by the HIV-1 gp120 is mediated through the V3
loop, a fragment of gp120. The binding of the V3 loop to CXCR4 or CCR5 determines the cell tropism of HIV-1 and constitutes a
key step before HIV-1 cell entry. Thus, elucidating the molecular recognition of CXCR4 by the V3 loop is important for under-
standing HIV-1 viral infectivity and tropism, and for the design of HIV-1 inhibitors. We employed a comprehensive set of compu-
tational tools, predominantly based on free energy calculations and molecular-dynamics simulations, to investigate the
molecular recognition of CXCR4 by a dual tropic V3 loop. We report what is, to our knowledge, the first HIV-1 gp120 V3
loop:CXCR4 complex structure. The computationally derived structure reveals an abundance of polar and nonpolar intermolec-
ular interactions contributing to the HIV-1 gp120:CXCR4 binding. Our results are in remarkable agreement with previous exper-
imental findings. Therefore, this work sheds light on the functional role of HIV-1 gp120 V3 loop and CXCR4 residues associated
with HIV-1 coreceptor activity.INTRODUCTIONThe primary step of human immunodeficiency virus type 1
(HIV-1) cell entry is the interaction of the viral envelope
glycoprotein (comprising subunits gp41 and gp120) with
the host leukocyte glycoprotein receptor, CD4, and the
two chemokine receptors CXCR4/CCR5 on the surface of
the host cells (1–5). Specifically, the glycoprotein gp120
interaction with CD4 triggers conformational changes in
gp120 that increase the exposure of the third variable region
(V3) loop. Subsequently, the protein gp120, via its V3 loop,
binds to chemokine receptors CXCR4 (infecting mostly
T-cells) or CCR5 (infecting mostly macrophages) (6–11).
The molecular recognition of chemokine receptors by the
V3 loop results in a series of rearrangements in the envelope
glycoprotein, leading to the fusion of the virus and the cell
membranes (12).
At the beginning of the 1990s, the V3 loop was identified
as the primary determinant of cell tropism in HIV-1 (13).
Since the discovery of the key role of V3 loop in HIV-1
infection, with regard to the binding to chemokine receptors
CXCR4 and CCR5 (6,14,15) and the determination of cell-
tropism (13), recognizing CXCR4 or CCR5 or both
(referred to as ‘‘dual tropic’’), several experimental studies
aimed at elucidating the key interacting residues of chemo-
kine receptors involved in the V3 loop binding through the
mapping of the chemokine receptors’ binding sites (16–26).
These studies employed site-directed mutagenesis or
chimeric substitutions, and identified specific residues or
residue moieties of the chemokine receptors that are critical
to, or correlate with, viral infection.
The HIV-1 gp120 V3 loop is sustained in a loop confor-
mation through a disulfide bridge between its N- and C-ter-Submitted May 23, 2013, and accepted for publication July 29, 2013.
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0006-3495/13/09/1502/13 $2.00minal ends, is encountered in a large sequence variability, is
positively charged, and is predominantly composed of 35
residues (27–29). Owing to its highly dynamic character
(27,29,30), the V3 loop is absent in the majority of gp120
crystallographic structures; nevertheless, it was resolved in
two crystallographic Protein Data Bank (PDB) entries
(4,5). Numerous studies aimed at understanding the physi-
cochemical properties of the V3 loop and elucidating its
viral tropism (5,11,19,26,31–34). It has been suggested
that charge complementarity and electrostatic interactions
among the N-terminal, extracellular loop 2 (ECL2) corecep-
tor domains, and the V3 loop (5,11,19,26,31–33), are asso-
ciated with the viral tropism. Furthermore, it has been
proposed that the interchange from coreceptor CCR5 to
CXCR4, as the disease progresses, is linked to 1), The in-
crease of the net charge of the V3 loop (10,31); 2), The pres-
ence of positively charged residues at one or more of
positions 11, 24, and 25, known as the 11/24/25 rule (9);
and 3), The absence of the glycosylation motif
N6X7T8jS8X9 (where X ¼ Pro) (8).
Recently, molecular dynamics (MD) simulations showed
that V3 loops undergo common correlated motions, in asso-
ciation with specific charged interactions between residues
on opposite stems (27). Understanding the unbound proper-
ties of gp120 domains is important for delineating the mech-
anism of conformational changes from unbound to bound
structures, related to gp120:CD4 binding (35,36). Similarly,
the identification of unbound V3 loop conformations associ-
ated with electrostatic-driven correlated motions (27) could
prove significant for the elucidation of the gp120 (V3
loop):CXCR4 binding.
Despite the numerous studies related to the V3 loop and
the chemokine receptors, the basic biological knowledge
on the specific interactions between the V3 loop and the
chemokine receptors is limited due to the absence of ahttp://dx.doi.org/10.1016/j.bpj.2013.07.049
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could be associated with the high flexibility of the V3
loop leading to absence of electron density in the gp120
crystal structures, as in Liao et al. (37).
A comprehensive attempt to computationally derive a V3
loop:CXCR4 complex structure to enlighten the role of the
key interacting V3 loop and CXCR4 residues has never
before been reported, according to our knowledge. In this
study, we exploit both the CXCR4 crystallographic structure
(11) and one of the V3 loop crystallographic structures (5) to
theoretically derive what is, to our knowledge, the first V3
loop:CXCR4 complex structure using a combination of pri-
marily binding/interaction free-energy calculations and MD
simulations. The computational protocol applied was not
biased by any experimental evidence regarding the key in-
teracting residues, and interestingly, our results are in
remarkable agreement with previous experimental findings
(see Table 1; marked in boldface are CXCR4 residues re-
ported in experimental findings) (16–21,23–25). Thus, the
reported V3 loop:CXCR4 complex structure sheds light
on the functional role of V3 loop and CXCR4 residues,
which are experimentally determined as critical for the
HIV-1 coreceptor activity.METHODS
Modeling, free energy calculations, andmolecular
dynamics simulations
The methodology used in this study to derive the V3 loop:CXCR4 complex
structure consists of the seven following principal steps.
Step 1: Modeling and selection of the initial V3 loop and
CXCR4 structural conformations
V3 loop. The initial backbone structural conformation of the V3 loop cor-
responds to PDB:2QAD, one of the two intact crystal structures of gp120
in the Protein Data Bank (PDB) (5). V3 loop residues 296–331 of
PDB:2QAD were renumbered, starting from 1 and ending at 35. The
gp120 residues outside the V3 loop were not considered for investigation
in this study because the V3 loop region is the principal determinant of
chemokine receptor specificity (2), and the presence of a disulfide bridge
between the N- and C-terminal residues of V3 loop base constitutes a phys-
ical constraint for the preservation of the structure in the base region. In
addition, according to a recent MD study, the V3 loop does not have
any strong concerted motion with other parts of the gp120 protein but
only within residues of the V3 loop (29). To identify a representative
dual-tropic CXCR4/CCR5 V3 loop to examine in this study, we utilized
the CD-HIT (38) to perform a sequence-based clustering on the dual tropic
V3 loops, which was deposited in the Los Alamos National Laboratory
(Los Alamos, NM) database (http://www.hiv.lanl.gov). According to the
results, we identified the following sequence of subtype B as the centroid
of the most populated dual tropic cluster (extracted from a Chinese
patient),
CTRPNNNTRKRVSLGPGRVWYTTGQIVGDIRKAHC;
which obeys the 11/24/25 rule (8). In what follows, we use this particular
sequence to derive the V3 loop:CXCR4 structure.CXCR4. The initial structural templates used to construct the CXCR4
conformation correspond to PDB:3OE0 (11) and PDB:2K05 (39) (humanfragment containing the missing N-terminal residues 1–24 of PDB:3OE0
(11)); the two fragments were combined using pairwise alignment on their
overlapping regions. The FREAD loop modeling algorithm, was applied to
model the missing loops (40), and the I-TASSER server was used to model
the missing C-terminal residues (41).
Step 2: Production of flexible templates for V3 loop and
CXCR4 using MD simulations
V3 loop. We performed replica exchange MD simulations of the V3 loop so
as to enhance its conformational sampling (42–45). Solvent effects were
taken into account by the FACTS19 implicit solvent model (46). The im-
plementation of implicit solvent models (47), including the particular
one used in this study, FACTS (46), in conjunction with the replica ex-
change MD scheme, successfully balances fast exploration of the confor-
mational space with accuracy, to reproduce results from explicit solvent
MD simulations (48,49). The simulations were conducted with the molec-
ular mechanics program CHARMM, Ver. c35b6 (50). The average root
mean-square deviation (RMSD) of the conformations produced at 300 K
with regard to the starting conformation upon minimization is 5.1 5
1.3 A˚. The result demonstrates that this dual tropic V3 loop encounters a
high flexibility in the unbound simulations, and the computational protocol
used has successfully sampled the conformational space in order to pro-
duce representative flexible templates for docking. Additional information
regarding the simulation protocol and parameterization is provided in the
Supporting Material.
CXCR4. We employed MD simulations to produce multiple flexible tem-
plates for the human CXCR4 protein receptors and to refine the modeled
regions of CXCR4. Because the goal was not only to refine the structure
but also to produce flexible templates that could constitute docking recep-
tors, we considered that a preliminary docking of V3 loop on CXCR4
would be beneficial for the subsequent docking procedure. Thus, we used
the software CLUSPRO 2.0 (51) to primarily dock a V3 loop, correspond-
ing to the PDB:2QAD conformation (5), on the modeled CXCR4, and we
produced three conformations with different poses of the V3 loop proximal
to the experimentally defined binding site. For each of the three complex
structures yielded, we performed two independent MD simulations to pro-
duce flexible template structures for CXCR4. Within the MD simulations,
the system was immersed in an implicit membrane represented by the
switching-function generalized Born (GBSW) module (52,53). The mem-
brane thickness Tmemb was set to 36 A˚ with one-half of the membrane
switching length equal to 2.5 A˚; the choice of these values complies with
the approximate intramembrane helical length of CXCR4 (11), and was
shown to provide optimal protein stability compared to test simulations
with larger or smaller. The surface tension coefficient was set to
0.03 kcal/(mol*A˚2); all other parameters were set to default values (54).
The simulations were conducted with the molecular mechanics program
CHARMM, Ver. c35b6 (50). Additional information regarding the simula-
tion protocol and parameterization is provided in the Supporting Material.
Step 3: Docking of selected V3 loop structures on selected
CXCR4 structures
We clustered the structures produced in the V3 loop replica exchange MD
simulations as well as the CXCR4 structures produced from the six inde-
pendent aforesaid MD simulations using the quality clustering method of
the command line utility WORDOM (55). We extracted the 20 most popu-
lated clusters for the V3 loop, and 17 clusters for CXCR4, including the
initially modeled CXCR4 structure. Additional information is provided in
the Supporting Material.
Subsequently, we used the parallel LINUX version of the ZDOCK Ver.
3.0.2 (56) to dock the 20 V3 loop clustered structures on the 17 CXCR4
clustered structures. For each run of ZDOCK, 2000 docked structures
were produced with a dense rotational sampling and a masking applied
on the region with protein coordinates z < 0 A˚, so as to exclude the nonpo-
tential binding region from the docking calculations. As a result, 680,000
complex structures were produced from docking.Biophysical Journal 105(6) 1502–1514
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energy calculation of the docked complexes using the mem-
brane-GBSA approximation
All 680,000 complexes were subjected to 100 steps of steepest-descent
minimization to alleviate bad contacts and, the binding free energy was
evaluated subsequently for all complexes using the generalized Born
(GB) solvent-accessible (SA) approximation in a heterogeneous water-
membrane-water environment, modeled by GBSW (53). The binding free
energy is evaluated via the expression
DG ¼ EPL  EP  EL;
where EX is the total (free) energy of molecule X (complex PL:CXCR4:V3
loop, free protein P:CXCR4, or free ligand L:V3 loop) as in the literature
(57–59). The protein and ligand conformations were assumed identical in
the complex and in their free (unbound) states as in the literature (60–
64). With this assumption, any bonded-energy contributions to DG are
canceled in the equation. The solvation free energy components of the com-
plex and unbound protein were computed in the heterogeneous membrane/
water environment, while the solvation free energy component of the un-
bound ligand was computed in a homogeneous aqueous environment,
also modeled by the implicit GBSW model (52,53).
Step 5: Second round of energy minimization and binding free
energy calculations of the docked complexes using the
membrane-PBSA approximation
Out of the 680,000 complexes, we selected the 9000 V3 loop:CXCR4 com-
plexes with the lowest GBSA binding free energy, and subsequently, we
performed an additional round of 100 steps steepest-descent minimization
and calculated the binding free energy using the Poisson-Boltzmann (PB)
SA approximation (57). At the end of this procedure, we identified the com-
plex structure with the lowest binding free energy 144.2 kcal/mol, and
additionally, we selected all the complex structures within a 10-kcal/mol
range of the lowest binding free energy (144.2:134.1 kcal/mol) for sub-
sequent investigation. As a result, the total number of complex structures
selected for subsequent investigation was 17. Table S1 in the Supporting
Material presents the binding free energies of the 17 different complex
structures produced in Step 5. Additional information regarding the PB cal-
culations and the results is provided in the Supporting Material.
Step 6: MD simulations of the docked complexes acquiring
the lowest binding free energy
We performed 17 independent MD simulations of the complexes with the
lowest PBSA binding free energies, as identified in the previous step.
The MD simulations comprised a 400-ps heating procedure and an addi-
tional 700-ps equilibration procedure at which the harmonic restraints
were gradually removed from the protein and the peptide. No restraints
were imposed during the production run at 300 K, the duration of which
was equal to 20 ns for every individual complex. The simulation methodol-
ogy and force-field parameterization used was identical to Step 2, at which
point we also performed MD simulations in implicit membrane to produce
flexible templates for CXCR4.
Step 7: Binding free energy calculations of the complex
structures produced in the MD simulations to identify the
complex structure with the lowest average binding free
energy
We extracted 1000 snapshots, corresponding to 20-ps intervals, from the 17
MD 20-ns simulations and reevaluated the binding free energy by employ-
ing the MM PBSA approximation (57) (using the parameters presented in
Step 5). Interestingly, the MM PBSA calculation of the average binding
free energies for each complex expanded the free energy range from
[144.2:134.1 kcal/mol] in step 5 to [367.2:275.2 kcal/mol] in Step
7 (see Table S1). The complex with the lowest average binding free energyBiophysical Journal 105(6) 1502–1514in this step, according to both MM PBSA and supplementary MM GBSA
calculations (58,59,60–64), corresponds to the complex structure of Step
5, which also possesses the lowest binding free energy (144.2 kcal/mol;
see Table S1). The change in the binding free energy ranking among Steps
5 and 7, as well as the improvement of interactions leading to lower binding
free energies in Step 7 compared to Step 5, emphasize the key role of con-
ducting MD simulations a posteriori to docking.
In what follows, we present the methodology used to investigate pairwise
residue interaction free energies of the complex structure possessing the
lowest average binding free energy.Analysis of interaction free energies of V3 loop:V3
loop and V3 loop:CXCR4 residue pairs
The interaction free energies between two residues (R and R0) were
computed by the relation
DGintRR0 ¼
X
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X
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
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
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The first and second group of terms on the right-hand side of Eq. 1 describe,
respectively, polar and nonpolar interactions between R and R0. For the
investigation of V3 loop:CXCR4 intermolecular interactions, R corre-
sponds to a V3 loop residue and R0 to a CXCR4 residue. For the investiga-
tion of V3 loop intramolecular interactions, both R and R0 correspond to V3
loop residues. To compute the Eij
GB term in Eq. 1, we included all protein
(CXCR4) and ligand (V3 loop) atoms and set the charges of atoms outside
the two residues R and R0 under investigation to zero. The generalized-Born
energies and the atomic accessible-surface areas (DSi) entering in Eq. 1
depend on the location of R and R0 in the complex. The polar component
contains a Coulombic term and a GB contribution, modeling the interaction
between group R and the solvent polarization potential induced by R0. Simi-
larly, the nonpolar component contains a van der Waals interaction between
R, R0 and a surface term, expressing cavity contributions and nonpolar in-
teractions with the surrounding solvent. The last term contains the differ-
ence in solvent-accessible surface areas of residues R and R0 in the
complex and unbound states (62–64). The analysis was performed using
all 1000 snapshots from Complex 1. The nonpolar and polar solvation terms
were calculated using the heterogeneous membrane-water GBSWusing the
same parameters of step 4. The sum of the two components reflects the total
direct interaction between R and R0 in the solvated complex (62,63,64).
We decomposed the polar and nonpolar interaction free energy contribu-
tions and present the results of the average interaction free energies of the
lowest binding free energy complex in two-dimensional density maps in
Fig. S1 and Fig. S2 in the Supporting Material. In addition, we calculated
the average interaction energy per V3 loop residue, by summing up the
interaction energies of the specific residue with all of its possible CXCR4
interacting residues, so as to investigate the critical gp120-V3 loop residues
with regard to coreceptor binding. The results are presented in Table S4.RESULTS
We employed a comprehensive set of computational tools,
primarily comprising binding free energy calculations and
MD simulations, and identified Complex 1 as the MD simu-
lation with the lowest average binding free energy (Fig. 1,
and see Table S1). In all 17 complexes, the V3 loop residues
lying outside the chemokine receptor experience higher
flexibility; the average backbone RMSD without alignment
Molecular Recognition of CXCR4 by HIV-1 gp120 1505with respect to the starting simulation conformation is
3.9 5 0.3 and 2.9 5 0.1 A˚ for the entire V3 loop and the
embedded region (8:26), respectively, in Complex 1 (see
Table S2). In general, in the lowest binding free energy com-
plexes (1, 4, and 12) the V3 loop possesses a relatively low
RMSD average and standard deviation values, specifically
within the residue moiety 8–26 (see Table S2). On the con-
trary, the unbound V3 loop is considered to be highly flex-
ible as shown in Methods, in line with (27,29,30).
Therefore, the results of this study indicate that the corecep-
tor binding stabilizes the conformation of the V3 loop, espe-
cially for the V3 loop residue moiety 8:26. In addition, at
least for the lowest binding free energy complexes (1, 4,
and 12), the V3 loop binding also provides stabilization
for the N-terminal end of CXCR4 (see Table S2).
The nonpolar binding free energy of Complex 1 is com-
parable to Complex 4. However, according to both GB
and PB approximations, the polar component of Complex
1 is more favored than Complex 4. According to the analysis
of hydrogen-bond interactions of all complexes (see Table
S3), this is mainly due to the absence of salt bridges between
V3 loop:CXCR4 residues Arg3:Glu268, Arg18:Asp171, and
Arg31:Glu14 in Complex 4 (see Table S3). Also, the lower
polar binding free energy of Complex 12, compared to
Complex 1, according to both GB and PB calculations,
could mainly be attributed to the presence of additional
salt bridges between V3 loop:CXCR4 residues Arg11:Asp10
and to a lesser extent Arg9:Asp10, Lys10:Tys12 (see Table
S3); in addition, the salt bridge of Arg31 with residue
Glu14 in Complex 1 is interchanged with a lower occupancy
salt bridge with residue Tys12 in Complex 12. On the con-
trary, Arg3:Asp22 and Arg3:Glu268 have lower occupancy
in Complex 12 compared to 1. Nevertheless, despite the
lower polar binding free energy of Complex 12 compared
to Complex 1, the nonpolar component of Complex 1 is
more favored compared to Complex 12 by ~24 kcal/mol,
and overall Complex 1 is the most favored among all com-
plexes. In what follows, we oriented our analysis to Com-
plex 1, as its binding free energy is optimum compared to
other complexes with regard to the sum of polar and
nonpolar binding components, and provide a detailed inves-
tigation of the structural and physicochemical properties
encountered within the 1000 frames extracted from the
simulation.Structural properties of the bound V3 loop
Residues 8–26 of the V3 loop are buried within CXCR4,
whereas residue moieties 1–7 and 27–35 mainly lie upon
the N-terminal end of CXCR4 (all V3 loop residues are re-
numbered, starting from 1 and ending at 35). The V3 loop
conformation is twisted, as shown in Fig. 1 and, two consec-
utive antiparallel b-sheets among the following residue moi-
eties, 12–13:22–21 and 3–9:32–26, are observed in the
trajectory. A b-turn or bend is observed within the core ofthe tip comprising residues 16:20, which is the mostly
buried region of the V3 loop within the binding pocket, as
shown in Fig. 1. The b-sheets provide a compact-thin shape
and a relatively stable conformation of the V3 loop within
the simulation. The two primary hydrogen bonds involving
side chains of opposite V3 loop stems are Arg9 NH1/2:Gln25
OE1 and Thr8 O:Arg31 NH1/2. The relatively tight binding
of a highly flexible loop can be attributed to both the coop-
erativity of intramolecular interactions in the bound struc-
ture, shown in Fig. S1, and the intermolecular interactions,
analyzed below.Investigation of the V3 loop: CXCR4 complex
structure
We present a detailed overview of the structural and physi-
cochemical properties of the complex structure, which is
based on the assessment of the intermolecular pairwise res-
idue interaction free energies, shown in Fig. S2. Fig. 2 pre-
sents the most important intermolecular polar interactions in
the trajectory, using the software VMD (65). Table 1 ex-
tracts information from Fig. S2 as well as Table S3 and sum-
marizes the key interactions between V3 loop:CXCR4
residues, over all 1000 snapshots, and features in boldface
the agreement with experimental findings.
The coordinates of structures in Complex 1, extracted
every 2 ns, are provided (see Supporting Material). Within
the simulation, the conformation of the coreceptor is very
well retained with regard to the starting simulation structure.
The average backbone RMSD of the intramembrane helical
residues is equal to 1.35 0.0 A˚, and the average RMSD of
the entire backbone is 2.25 0.2 A˚. The larger value of the
latter is attributed to the higher flexibility of the non-intra-
membrane domains. It is worth noting that in all simula-
tions, the average backbone RMSD of the intramembrane
helical residues is low (see Table S2), showing the ability
of the implicit solvent model used to preserve the integrity
of the x-ray structure (11).Interactions of V3 loop residues 1:15 with CXCR4
V3 loop residues 3–15 are mainly engaged to intermolecular
interactions with the N-terminal end of CXCR4 and to a
lesser extent with ECL2 and ECL3 residues of CXCR4.
Cys1, Thr2, and Pro4 of the V3 loop are predominantly sol-
vent-exposed. Arg3 of the V3 loop forms a highly interact-
ing salt bridge with Glu268, a salt bridge with CXCR4
residue Asp22 (Fig. 2 A), and is also proximal to the nega-
tively charged Asp20 and Tys21. Asn5 of the V3 loop interca-
lates between CXCR4 residues Asp20, Tys21, Asp22, and
Ser23; two simultaneous hydrogen bonds are observed:
Asn5 ND2:Tys21 O and Asn5 ND2:Asp20 OD1/2. Asn6 of
the V3 loop mainly interacts with CXCR4 residue Ser23;
as a result, two simultaneous hydrogen bonds are frequently
formed among atom pairs Asn6 N:Ser23 OG and Asn6 ND2/Biophysical Journal 105(6) 1502–1514
FIGURE 1 Molecular graphics image of the entire simulation system
corresponding to the complex with the lowest average binding free energy.
The V3 loop is shown in tube and transparent surface representation in red
color, and its 16–20 residue moiety is shown in thick tube representation.
The CXCR4 is shown in cartoon representation, and the coloring used
for different protein domains is as follows: (blue) N-terminal domain;
(green) intramembrane helix 1 (IH1); (light gray) intracellular loop 1
(ICL1); (purple) IH2L; (light gray) ECL1; (yellow) IH3; (light gray) ICL
2; (medium gray) IH4; (ochre) ECL2; (pink) IH5; (light gray) ICL3;
(cyan) IH6; (lime) ECL3; (orange) IH7; and (light gray) C-terminal
domain. (van der Waals sphere) N-terminal Ca atom of CXCR4. (Thick
transparent licorice representation) V3 loop disulfide bridge. The definition
of CXCR4 and V3 loop domains is presented in the Supporting Material
(colors appear in the online version only).
1506 Tamamis and FloudasOD1:Ser23 OG. Because position 6 is an N-linked glycosyl-
ation site, we assume that apart from the loss of the afore-
mentioned hydrogen-bond interactions, the N-linked
glycosylation will not interfere with the binding as, accord-
ing to the simulation, the side chain of Asn6 points toward
the aqueous environment. Asn7 of the V3 loop is mainly in-
teracting with CXCR4 residues Glu14 and Asn11 through
weak Asn7 OD1:Asn11 ND2, Asn7 ND2:Glu14 OE1/2
hydrogen bonds. Thr8 of the V3 loop intercalates between
the backbone moieties of CXCR4 residues Tyr21, Asp22,
Ser23, and Lys25; Thr8 OG1 is hydrogen-bonded to Asp22
O consistently during approximately the last half of the
simulation. Arg9 of the V3 loop interacts with the backbone
moieties of residues Met1, Tys7, Thr8, Ser9, Asp10, and
Asn11, as well as the side chain of CXCR4 residue Tys12.
Two hydrogen bonds are formed between the charged amide
group of Arg9 and the backbone carbonyl groups of Tys7
(Fig. 2 B) and Asp10; also, the proximity of the positively
charged amide group of Arg9 to the negatively charged
Tys12 results in a polar interaction between the two.Biophysical Journal 105(6) 1502–1514Lys10 of the V3 loop participates in a highly interacting
salt bridge with CXCR4 residue Asp193 (Fig. 2 A) and in
the following hydrogen bonds: Lys10 N:Tys12 SO(2/3),
Lys10 NZ:Asp20 O, and Lys10 NZ:Leu266 O (Fig. 2 B). In
addition, the nonpolar part of the Lys10 side chain is prox-
imal to the backbone of Ser18, Gly19, and the aromatic
ring of Tys21. Arg11 of the V3 loop is buried in a diverse
polar/nonpolar binding pocket comprising CXCR4 residues
Met1 (Fig. 2 B), Glu2, Gly3, Tys7, Tys12, Phe189, and Pro191;
its nonpolar side-chain part is proximal to the aromatic rings
of Tys7, Tys12, and Phe189, and its backbone amide is
hydrogen-bonded to Tys12 SO3; moreover, its charged
amide is close to the backbone of the first three CXCR4
N-terminal residues and is hydrogen-bonded to Met1 O
and Glu2 O. Val12 of the V3 loop forms nonpolar contacts
with nearby CXCR4 residues Phe189, Tyr190, and Val196.
Ser13 of the V3 loop is interacting mainly with Met1 through
the Ser13 OG:Met1 N hydrogen bond (Fig. 2 B). Leu14 of the
V3 loop is positioned between N-terminal and ECL2 of
CXCR4 residues. Its backbone is mainly interacting with
CXCR4 residues Glu2, Gly3 and, as a result, a low frequency
hydrogen bond is observed between Leu14 N and Glu2 O; in
addition the backbone carbonyl group of Leu14 is hydrogen-
bonded to the charged side-chain NH1 or NH2 Arg183 in
more than half of the simulation snapshots. The Leu14
side chain intercalates around residues Ser178, Ala180,
Ile185, Asp187, and Phe189. The placement of the charged
Asp187 in the vicinity of the hydrophobic Leu14 is attributed
to the hydrogen bond among Asp187 OD1 or OD2 with the
V3 loop atom Gly15 N (Fig. 2 B).Interactions of V3 loop residues 16:22 with
CXCR4
Pro16 of the V3 loop is buried within a binding pocket
composed of CXCR4 residues Arg30, Phe36, Asn37, and
Leu41, and its amide group forms a weak hydrogen bond
with atom Asn37 ND2. Gly17 of the V3 loop is mainly
involved in a hydrogen bond with Asp97 OD1/2 in approxi-
mately the last-quarter of the simulation; in addition it is
involved in a nonpolar interaction with residue Trp94 and
in a weak hydrogen bond with Tyr45 OH. Arg18 of the V3
loop forms the most highly interacting polar interactions
with a group of CXCR4 residues because it is simulta-
neously engaged in two high occupancy salt bridges with
residues Asp171 and Glu288 (Fig. 2 A). In addition, Arg18
NH1/2 is hydrogen-bonded to His203 NE2 (Fig. 2 B),
Thr117 OG1, Tyr255 OH, and the Arg18 backbone carbonyl
group is hydrogen-bonded to the charged amide of Arg188.
The nonpolar part of the Arg18 side chain is involved in
nonpolar contacts with residues Trp94 and Tyr116, and the
nonpolar moieties of Asp187 and Arg188. Val19 is involved
in mainly nonpolar interactions with its neighboring
CXCR4 residues Ile284 and Ser285. Trp20 of the V3 loop is
embedded in a binding pocket that mainly consists of
TABLE 1 Important intermolecular polar and nonpolar
interaction free energies, hydrogen bonds, and salt bridges,
between V3 loop and CXCR4 residue pairs within the MD
simulation of the complex with the lowest average binding free
energy
V3 loop
residueb
CXCR4 residues
(polar, nonpolar
interaction free
energies)c Salt bridgesd
Hydrogen
bondse
Arg3 Asp20 (0.0, 1.6)e
Tys21 (1.1, 2,4)
Asp22 (9.3, 2.5)
Glu268 (29.3, 2.6)
Arg3:Asp22
Arg3:Glu268
Asn5 Asp20 (2.9, 1.9)
Tys21 (1.1, 1.5)
Ser23 (2.2, 1.3)
Asn5 ND2:Asp20 OD*
Asn5 ND2:Tys21 O
Asn6 Ser23 (3.3, 2.3) Asn6 N:Ser23 OG
Asn6 ND2:Ser23 OG
Asn6 OD1:Ser23 OG
Asn7 Asn11 (0.1, 0.8)
Glu14 (1.9, 0.9)
Asn7 OD1:Asn11 ND2
Asn7 ND2:Glu14 OE*
Thr8 Tys21 (0.3, 2.9)
Asp22 (3.1, 0.7)
Lys25 (0.5, 2.1)
Thr8 OG1:Asp22 O
Arg9 Met1 (0.0, 1.9)
Tys7 (7.3, 1.2)
Ser9 (0.2, 1.6)
Asp10 (2.8, 1.0)
Tys12 (4.4, 5.0)
Arg9 NH*:Tys7 O
Arg9 NH*:Asp10 O
Lys10 Tys12 (9.5, 3.0)
Asp20 (8.5, 1.0)
Tys21 (1.0, 3.4)
Asp193 (17.8, 0.9)
Leu266 (6.7, 2.3)
Lys10:Asp193 Lys10 N:Tys12 SO*
Lys10 NZ:Asp20 O
Lys10 NZ:Leu266 O
Arg11 Met1 (7.9, 2.1)
Glu2 (0.9, 1.9)
Gly3 (1.2, 1.7)
Tys7 (1.0, 4.5)
Tys12 (2.3, 6.3)
Phe189 (0.1, 1.7)
Arg11 NH*/NE:Met1 O
Arg11 NH*:Glu2 O
Arg11 N:Tys12 SO*
Val12 Phe189 (0.1, 2.3)
Tyr190 (0.0, 3.2)
Ser13 Met1 (5.8, 1.9) Ser13 OG:Met1 N
Leu14 Glu2 (1.2, 1.4)
Gly3 (0.2, 1.7)
Ser178 (0.1, 1.7)
Ala180 (0.0, 2.4)
Arg183 (1.6, 1.0)
Ile185 (0.1, 2.5)
Asp187 (3.8, 3.4)
Phe189 (0.1, 1.6)
Leu14 N:Glu2 O
Leu14 O:Arg183 NH*
Gly15 Ile185 (0.1, 1.7)
Asp187 (6.3, 0.1)
Gly15 N:Asp187 OD*
Pro16 Arg30 (0.3, 2.0)
Asn37 (0.1, 2.2)
Pro16 N:Asn37 ND2
Gly17 Tyr45 (0.8, 0.6)
Trp94 (1.2, 1.7)
Asp97 (2.2, 0.1)
Glu288 (2.8, 0.1)
Gly17 N:Tyr45 OH
Gly17 N:Asp97 OD*
Arg18 Trp94 (0.1, 2.0)
His113 (3.2, 1.3)
Tyr116 (5.1, 2.5)
Thr117 (2.1, 1.0)
Asp171 (37.2, 0.3)
Arg18:Asp171
Arg18:Glu288
Arg18 NH*:Thr117 OG1
Arg18 O:Arg188 NH*/NE
Arg18 NH*:His203 NE2
Arg18 NH*:Tyr255 OH
Table 1. Continued
V3 loop
residueb
CXCR4 residues
(polar, nonpolar
interaction free
energies)c Salt bridgesd
Hydrogen
bondse
Asp187 (1.1, 1.4)
Arg188 (8.27, 3.1)
His203 (18.1, 0.4)
Tyr255 (2.8, 0.5)
Glu288 (65.6, 2.6)
Val19 Glu288 (2.7,1.0)
Trp20 Arg188 (4.8, 3.2)
Tyr190 (1.5, 1.7)
Val196 (0.1, 2.2)
Phe199 (0.0, 1.6)
Gln200 (1.5, 3.4)
His281 (0.9, 0.9)
Trp20 NE1:Arg188 NH*
Trp20 NE1:Tyr190 OH
Trp20 O:His281 ND1
Tyr21 Arg30 (0.2, 3.3)
Glu277 (0.2, 2.0)
Asn278 (1.2, 2.8)
His281 (0.2, 4.3)
Tyr21 OH:Asn278 ND2
Thr22 Leu266 (0.0, 1.8)
Glu277 (2.8, 0.8)
Thr22 OG1:Glu277 OE*
Thr23 Met1 (0.0, 2.1)
Cys28 (0.6, 1.8)
Thr23 OG1:Cys28 O
Gly24 Lys25 (0.4, 1.8)
Cys28 (3.2, 2.1)
Gly24 N:Cys28 O
Gly24 O:Cys28 N
Gln25 Met1 (0.1, 1.6)
Pro27 (0.0, 2.7)
Cys28 (0.4, 1.5)
Gln25 NE2:Cys28 O
Ile26 Lys25 (0.0, 1.7)
Val27 Ser9 (0.1, 1.7)
Asp10 (0.1, 1.7)
Asn11 (0.0, 1.9)
Arg31 Tys12 (1.8, 1.2)
Glu14 (16.8, 0.5)
Ser18 (0.2, 3.0)
Asp20 (8.4, 1.4)
Arg31:Glu14
Arg31:Asp20
Arg31 NH*:Ser18 OG
Lys32 Gly17 (3.4, 0.8)
Ser18 (3.1, 0.6)
Asp20 (16.4, 0.4)
Lys32:Asp20 Lys32 NZ:Gly17 O
Lys32 NZ:Ser18 O
His34 Asp20 (1.0, 1.5) His34 ND1:Asp20 OD2
CXCR4 residues marked in boldface are experimentally associated with
HIV-1 coreceptor activity (see Discussion). The results presented corre-
spond to analysis of 1000 snapshots. The asterisk (*) symbol used after
any V3 loop/CXCR4 atom in the hydrogen bonding pair denotes that any
of the atoms in the charged, carboxyl or amide, side-chain group can
participate in the hydrogen-bond formation.
aPrincipal interacting V3 loop.
bPrincipal interacting CXCR4 residue pairs.
cFor each pair, the average polar and nonpolar average interaction free en-
ergies (polar, nonpolar), are provided in parentheses next to each CXCR4
residue; all energies are in kcal/mol.
dSalt bridges between V3 loop and CXCR4 residue pairs.
eHydrogen bonds between V3 loop and CXCR4 atom pairs.
Molecular Recognition of CXCR4 by HIV-1 gp120 1507residues Arg188, Tyr190, Val196, Phe199, Gln200, and Ile284;
the interactions with Arg188 and Tyr190 are polarly driven
due to the Trp20 NE1:Arg188 NH1/2 and Trp20 NE1:Tyr190
OH hydrogen bonds, whereas the latter interactions mainly
involve nonpolar contacts. The backbone carbonyl group of
Trp20 is weakly hydrogen-bonded to CXCR4 atom His281Biophysical Journal 105(6) 1502–1514
FIGURE 2 Molecular graphics images of important polar interactions
corresponding to the complex with the lowest average binding free energy.
Panels (A) and (B) depict the salt bridges and the most important hydrogen
bonds, respectively, according to residue pair-wise interaction free energies.
Panel (B) is rotated by approximately 180 with respect to (A) around the z
(membrane) axis. The V3 loop is shown in tube and in red color, and its
16–20 residue moiety is shown in fat tube representation. The CXCR4 is
shown in light gray transparent tube representation. The salt bridge and
hydrogen bonds in panels (A) and (B) are denoted in dashed lines and the
participating V3 loop and CXCR4 residue moieties are shown in licorice;
V3 loop and CXCR4 residues are annotated in red and black, color respec-
tively. Hydrogen atoms are omitted for clarity and the V3 loop disulfide
bridge is shown in fat transparent licorice representation. (colors appear
in the online version only).
1508 Tamamis and FloudasND1. Tyr21 of the V3 loop is surrounded by CXCR4 resi-
dues Phe29, Arg30, Asn278, Glu277, and His281; its side-chain
hydroxyl group is hydrogen-bonded to CXCR4 atom Asn278
ND2/OD1 and the aromatic ring predominantly participates
in nonpolar interactions with the nonpolar moieties of these
residues. Thr22 of the V3 loop interacts with CXCR4 resi-
dues Leu266 and Glu277. The former residue interacts with
the nonpolar moiety of Thr22, whereas the latter residue isBiophysical Journal 105(6) 1502–1514involved in a Thr22 OG1:Glu277 OE1 hydrogen bond during
approximately the last-third of the simulation.Interactions of V3 loop residues 23:35 with
CXCR4
V3 loop residues 23–35 interact solely with the CXCR4
N-terminal region. Thr23 of the V3 loop forms nonpolar con-
tacts with CXCR4 residues Met1, the disulfide bridge resi-
due Cys28, and the backbone of Phe29, and in addition, its
side-chain hydroxyl group is weakly hydrogen-bonded to
the CXCR4 atom Cys28 O. Gly24 of the V3 loop is in prox-
imity with the nonpolar moiety of CXCR4 residue Lys25 and
interacts with the disulfide bridge CXCR4 residue Cys28 via
the Gly24 O:Cys28 N or Gly24 N:Cys28 O hydrogen bonds.
Gln25 of the V3 loop is in the vicinity of CXCR4 residues
Met1, Pro27, Cys28, and Phe29; its interaction with residue
Cys28 is facilitated through a low-occupancy hydrogen
bond between Gln25 NE2 and Cys28 O. Ile26 of the V3
loop is primarily interacting with the nonpolar moieties of
CXCR4 residues Ser23 and Lys25, and in a similar fashion,
Val27 of the V3 loop is buried within the nonpolar moieties
of CXCR4 residues Ser9, Asp10, and Asn11. Residues Gly28,
Asp29, and Ile30 of the V3 loop are solvent-exposed and are
not engaged in intermolecular interactions. Arg31 of the V3
loop forms two simultaneous salt bridges with CXCR4 res-
idues Glu14 and Asp20, with the former being stronger
(Fig. 2 A), and is proximal to oppositely charged residue
Tys12 and Ser18 of CXCR4; as a result its charged amide
is weakly hydrogen-bonded to Ser18 OG. Lys32 of the V3
loop forms a highly interacting salt bridge with CXCR4 res-
idue Asp20 (Fig. 2 A), and its charged amide group is
hydrogen-bonded to the backbone carbonyl groups of
CXCR4 residues Glu17 and Ser18. Residue Arg31 of the
V3 loop is proximal to the oppositely charged CXCR4 res-
idue Tys12, and residue Lys32 of the V3 loop participates in a
hydrogen bond through its charged amide group with the
backbone carbonyl group of CXCR4 Ser18. Residues
Ala33 and Cys35 of the V3 loop are solvent-exposed and
are not engaged in any interactions with CXCR4 residues,
whereas the side-chain amide group of V3 loop His34 is
weakly hydrogen-bonded to the charged carboxyl group of
CXCR4 Asp20. The disulfide bridge points toward the
aqueous environment throughout the simulation, as would
be expected if it was covalently bonded to the entire
gp120 protein.DISCUSSION
In the MD simulation, the bound V3 loop is twisted, and its
compactness is associated with the formation of b-sheets
and the Arg9 NH1/2:Gln25 OE1 hydrogen bond. These
data are in agreement with recently published results from
MD simulations of unbound V3 loops, according to which
the compactness was linked to an electrostatic interaction
Molecular Recognition of CXCR4 by HIV-1 gp120 1509between the side chains of residues Arg9 and Glu25 in one of
the V3 loops (27). The compact-thin shape of the V3 loop
bound structure suggests it is necessary for it to adopt a
compact-thin shape before coreceptor binding. The
compactness is related the maximization of the tip-base dis-
tance, as suggested in Lo´pez de Victoria et al. (27), and pro-
vides the ability to residue Arg18 for the V3 loop to be
buried deep inside the membrane and form highly interact-
ing polar interactions with CXCR4 residues Asp171 and
Glu288.
The average backbone RMSD of the unbound dual tropic
V3 loop conformations of this study compared to the most
representative, CCR5 tropic PDB:2QAD structures in solu-
tion (Fig. 7B, basins 1–3 of Lo´pez de Victoria et al. (27)) is
6.2 5 0.7, 5.4 5 1.4, and 7.7 5 0.8 A˚, respectively. The
corresponding values calculated for the residue moiety 8–
26 are 5.95 0.7, 4.65 1.6, and 7.75 1.0 A˚. The relatively
large values are in agreement with very recent results of
Chandramouli et al. (30) showing, respectively overall
structural dissimilarity between different tropic unbound
V3 loops, at the level of crown region, defined as residues
11–25. Nevertheless, upon alignment, the average backbone
RMSD between the bound dual tropic V3 loop conforma-
tions of Complex 1 for the last 5 ns, and the most represen-
tative, CCR5 tropic PDB:2QAD structure in solution with
maximized tip-base distance (Fig. 7B, basin 2 of Lo´pez de
Victoria et al. (27)) is 3.8 5 0.1 and 2.6 5 0.1 A˚, respec-
tively, for the entire V3 loop and the 8–26 residues moiety.
Thus, despite 1), the relatively large sequence dissimilarity
between the two V3 loops in 9 out of 35 positions, and 2),
the different simulation properties with regard to the V3
loop, bound versus unbound, the specific maximized tip-
base conformation (which can both adopt and is required
at least for CXCR4 binding) is interestingly comparable,
specifically for the 8–26 residue moiety.Key interacting V3 loop residues for CXCR4
recognition
The sum of the interaction energies per V3 loop residue,
presented in Table S4, presents the V3 loop residues associ-
ated with CXCR4 intermolecular interactions, in descend-
ing order. The 10 most highly interacting V3 loop
residues, with average total interacting free energies lower
than 20 kcal/mol are: Arg18, Lys10, Arg3, Arg31, Arg11,
Arg9, Trp20, Leu14, Lys32, and Tyr21. Seven out of ten are
positively charged and are highly interacting, predominantly
owing to strong polar interactions that involve salt bridges
and/or hydrogen bonds with CXCR4 residues. The specific
dual tropic V3 loop possesses a þ6 net charge, and within
the simulation of this study we observe an abundance of
highly interacting specific salt bridges and hydrogen bonds
between positively charged V3 loop residues and negatively
charged CXCR4 residues. This also supports: 1), The rule
implying that the increase of the net charge of the V3loop is associated with CXCR4 tropism (10,31); and
2), The suggestion that electrostatics likely dictate corecep-
tor choice (30).
Furthermore, it is worth noting that residues Arg18, Lys10,
Arg3, Arg31, and Arg9 possess the highest residue propensity
for their corresponding positions regarding both CXCR4
and dual tropic 35-residue-V3 loops, while residues Arg11
and Lys32 are the second most probable residues for posi-
tions 11 and 32 (see Table S4). Residues Trp20, Leu14, and
Tyr21 are highly interacting, predominantly owing to
nonpolar interactions with CXCR4 residues. Residue
Tyr21 possesses the highest residue propensity for position
21 for both CXCR4 and dual tropic 35-residue-V3 loops,
while residues Trp20 and Leu14 are the second most prob-
able residue for positions 20 and 14, respectively, after res-
idues Phe20 and Ile14 which are first, and possess similar
physicochemical properties (see Table S4). In addition,
the residues Pro16, Gly15, Ser13, Asn5, Gly17, Gln25,
Gly24, Val12, Thr8, Val19, Thr22, Thr23, Asn6, Val27, Ile26,
and Asn7 possess interaction free energies, in descending
order of strength, within the range of 14 to 5 kcal/mol
(see Table S4). Moreover, this study provides what is, to
our knowledge, the first reported molecular recognition-
based piece of evidence on the 11/24/25 rule (8), as Arg11
NH1/2 of V3 loop is hydrogen-bonded to Met1 O of
CXCR4. Taking into consideration that Met1 is the first
N-terminal residue, and that interactions between the V3
loop and CXCR4 N-terminal are critical for the molecular
recognition (19–21,24), this high-occupancy hydrogen
bond could be invaluable for reducing the high flexibility
of the N-terminal end (11) upon binding (see Table S2).
Since 1997, a series of experimental studies aimed at
exploring the key CXCR4 residues related to the V3 loop
interaction (16–22,24–26). A fraction of these studies also
aimed at comparing the CXCR4 residues associated with
V3 loop binding to the CXCR4 residues associated with
the stromal cell-derived factor1 (SDF1a) binding, because
SDF1a constitutes a natural ligand of CXCR4 with blocking
capacity of HIV-1 (66,67). In addition, some studies have
compared the CXCR4 residues associated with the V3
loop binding to the CXCR4 residues involved in the binding
of potential therapeutic candidates that act as V3 loop antag-
onists (68). The primary limitation of all studies reported
until now is the lack of information regarding the interacting
V3 loop:CXCR4 key residue pairs, due to the absence of a
published complex structure.Role of the N-terminal of CXCR4
The deletion of CXCR4 residues 2–25 is associated with at
least 60% reduction of HIV-1 coreceptor activity (17). The
same residue moiety is also critical for SDF1a and DV1
dimer binding, where DV1 dimer is a CXCR4 HIV-1 inhib-
itor (68). Our results show that more than half of the V3 loop
residues, mainly residues of the opposite stems, interactBiophysical Journal 105(6) 1502–1514
1510 Tamamis and Floudaswith the 2–25 CXCR4 residue sector. Alanine substitutions
to sulfated tyrosines 7 and 12 correlate with or markedly
impair the coreceptor activity for HIV-1 for different dual
tropic V3 loops (19,24). According to our results, Tys7 is
proximal to oppositely charged residues Arg9 and Arg11 of
the V3 loop, and its backbone carbonyl is hydrogen-bonded
to the charged side-chain group of Arg9. It is worth noting
that the functional role of some CXCR4 residues could be
associated with their intramolecular interactions because
they can be fundamental in stabilizing the coreceptor struc-
ture. Within the simulation, we observe that Tys7 SO24 is
mainly hydrogen-bonded with the CXCR4 backbone amide
groups of Ile4 and Ser5, contributing to the stabilization of
the 3–6 b-turn in CXCR4. Tys12 is attracted to oppositely
charged residues Arg9, Lys10, and Arg11 of the V3 loop,
and is stabilized in proximity to Lys10 and Arg11 via simul-
taneous hydrogen bonds among its charged SO4 side-chain
group and the backbone amide groups of Lys10 and Arg11.
Additional alanine substitutions on CXCR4 N-terminal
residues Glu2, Asp10, Glu14, Glu15, Asp20, Tys21, Asp22,
Ser23, Lys25, Glu26, Cys28, and Glu32 lead to a decrease of
HIV-1 coreceptor activity, showing that they are associated
with V3 loop binding (19–21,24). In the MD simulation,
Glu2 of CXCR4 is proximal to the oppositely charged
Arg11 of the V3 loop, and owing to its position, it contributes
to the stabilization of the polar interaction among the latter
and CXCR4 residue Met1. Asp10 of CXCR4 is polarly at-
tracted to oppositely charged Arg9 of the V3 loop and its po-
sition is stabilized by a hydrogen bond through its backbone
carbonyl group with the side-chain amide of V3 loop residue
Arg9. The charged side-chain carboxyl group of CXCR4
Glu14 forms a highly interacting salt bridge with the V3
loop residue Lys32 and a hydrogen bond with V3 loop
atom Asn7 ND2. Glu15 of CXCR4 points toward the oppo-
site side of the binding site and is not directly related to
the binding with V3 loop; nevertheless, as both Glu14 and
Glu15 correlate with HIV-1 coreceptor activity, the interac-
tions formed by Glu14 can be interchanged by its neigh-
boring Glu15. Asp20 of CXCR4 forms two highly
interacting salt bridges with residues Arg31 and Lys32, as
well as hydrogen bonds with residues Asn5, Lys10, and
His34. Residue Tys21 of CXCR4 is proximal to V3 loop res-
idues Thr8 and Lys10, forming noteworthy nonpolar interac-
tions. The critical role of CXCR4 residue Asp22 could
mainly be attributed to its high-occupancy salt bridge with
V3 loop residue Arg3. Ser23 of CXCR4 participates in
hydrogen bonds between its side-chain hydroxyl group
with main- and side-chain atoms of V3 loop residue Asn6.
Residue Asp25 of CXCR4 forms noteworthy nonpolar inter-
actions with V3 loop residues Thr8, Gly24, and Ile26. Resi-
due Glu26 of CXCR4 is weakly interacting with V3 loop
residues Gly24, Gln25, and Ile26, while residue Glu32 of
CXCR4 is not part of the binding pocket.
We observe the presence of intramolecular hydrogen
bonds and salt bridges between the N-terminal side chainsBiophysical Journal 105(6) 1502–1514and ECL3 side/main chains of CXCR4 residue pairs
Tys21:Gly272, Asp22:Lys271, Glu26:Gly273, and Glu32:Lys282.
The aforementioned interactions involve the Tys21, Asp22,
Glu26, and Glu32 N-terminal CXCR4 residues, which are
associated with HIV-1 coreceptor activity. The interactions
can be fundamental and constitute a sufficient condition
for the proper connection of the N-terminal end and ECL3
of CXCR4, as the deletion of the Cys28-Cys274 disulfide
bridge affects, but not to a large extent, the HIV-1 coreceptor
activity (20). Therefore, the side chains of CXCR4 residues
Tys21, Asp22, Glu26, and Glu32 can play a key role in the
preservation of the appropriate CXCR4 structure required
for the gp120 binding through its V3 loop.
The interactions reported in this study between the V3
loop and the CXCR4 N-terminal end are not similar to the
predicted interactions between the V3 loop and the CCR5
N-terminal end by Huang et al. (5) using molecular docking.
This variation can mainly be attributed to the facts that 1),
the N-terminal conformations of CXCR4 (39) and CCR5
(5) are different, and 2) CXCR4 and CCR5 V3 loops mainly
differ owing to their stem-region residues, which predomi-
nantly interact with the N-termini of the coreceptors. In
line with this suggestion, a recent analysis indicated that
the critical sites of features informative of viral tropism
belong to stem regions (69).Role of intramembrane helices 1 and 2 of CXCR4
Alanine substitutions showed a decrease in HIV-1 corecep-
tor activity for Tyr45 (17,68), Asp97 (17,18,20), to a lesser
extent for His79 (17,18,68) and Phe87 (18), but not for
Lys110 and Tyr121 (18). In line with this, Lys110 and
Tyr121, are not involved in interactions with the V3 loop
in the simulation. On the contrary, both Tyr45 and Asp97
of CXCR4 interact through their side chains with mainly
the carbonyl backbone group of Gly17. According to our
simulation, residue Phe87 of CXCR4 is indirectly involved
in the V3 loop binding by forming p-p interactions with res-
idue CXCR4 residue Tyr116, which directly interacts with
Arg18; the Phe87-Tyr116 interaction is also present in the
crystallographic structure (11). According to both the crys-
tal structure (11) and our findings, His79 is far from the bind-
ing site and it is hydrogen-bonded through its side-chain
amide group to Tyr157 OH of CXCR4.Role of ECL2 of CXCR4
Studies have shown that alanine substitution on residues
Trp161 and Pro163 correlate with the HIV-1 activity
(17,18). In both the crystallographic structure (11) and our
simulation, residues Trp161 and Pro163 are positioned in
the center of the membrane, away from the binding site;
we hypothesize that these residues play a role in the preser-
vation of the helical shape of intramembrane helix 4. Asp171
of CXCR4 is experimentally considered one of the most
Molecular Recognition of CXCR4 by HIV-1 gp120 1511important residues involved in the HIV-1 coreceptor activity
(17,18) because an alanine substitution at this position re-
duces by >60% the activity of both HIV-1 (17) and of
DV1 (68). Within our simulation, Asp171 of CXCR4 forms
a highly interacting salt bridge with V3 loop Arg18. Despite
the fact that Asp182 of CXCR4 is not part of the binding site,
also according to the CXCR4 crystal structure (11), its
alanine substitution results in a reduction of HIV-1 corecep-
tor activity (18). Asp182 can play a key role in attracting the
positively charged V3 loop before its binding, because
Asp182 possesses the peak position in ECL2 facing toward
the aqueous extracellular region in our simulation and the
crystallographic structure (11). Alanine substitutions re-
vealed that Arg183 (21,23), and to a lesser extent Tyr184
(21,23) of CXCR4, are related to HIV-1 coreceptor activity.
Within the simulation trajectory, the charged amide side
chain of Arg183 is involved in a hydrogen bond with the
backbone carbonyl group of V3 loop residue Leu14, while
its nonpolar side-chain moiety is proximal to Leu14 and
Gly15 of the V3 loop.
In line with the experimental structure (11), residue
Tyr184 is not in the binding site and it faces toward the
aqueous extracellular environment, in similar fashion to
Asp182; consequently it can play a role in attracting the posi-
tively charged V3 loop before its binding through its side-
chain OH group. Furthermore, alanine substitutions at
CXCR4 residues Asp187 and Phe189 are experimentally
associated with a >60% reduction for HIV-1 coreceptor ac-
tivity, suggesting the critical role of both residues (17,23). In
line with it, the charged carboxyl group of Asp187 is
hydrogen-bonded to atom Gly15 N of the V3 loop
throughout the entire simulation trajectory and its nonpolar
moiety is interacting with the proximal V3 loop Leu14 side
chain. In the simulation, Phe189 is buried in a nonpolar core
composed by V3 loop side chains of residues Arg11
(nonpolar moiety), Val12 and Leu14. Moreover, site-directed
mutagenesis studies have depicted an involvement of
the CXCR4 residues Arg188, Tyr190, and Pro191
(17,18,20,21,23) in the HIV-1 binding. In our simulation,
the Arg188 charged amide group is hydrogen-bonded atoms
Arg18 O and Trp20 NE1 atom of the V3 loop, the Tyr190 side
chain is also hydrogen-bonded to Trp20 NE1 and forms
nonpolar interactions with Val12 of the V3 loop, and
Pro191 is also proximal to Val12 of the V3 loop. The corecep-
tor activity is experimentally markedly impaired by an
alanine substitution at 193 for a specific HIV-1 strain (19);
in agreement with this, in our simulation Asp193 forms a
highly interacting salt bridge with V3 loop residue Lys10.Role of intramembrane helices 5, 6, 7 and ECL3
of CXCR4
An alanine substitution on CXCR4 residue Gln200 affects
significantly the HIV-1 coreceptor binding (21), and our re-
sults show that Gln200 forms a strong nonpolar interactionwith the aromatic ring of the V3 loop residue Trp20. This
interaction is additionally stabilized by an intramolecular
hydrogen bond between atoms Gln200 NE2 and Asp262
OD2, and an alanine substitution to Asp262 also reduces the
HIV-1 coreceptor activity (17,18). Furthermore, an alanine
substitution of CXCR4 residue Trp252 is related to a decrease
of the binding affinity of the V3 loop, SDF1a, and the DV1
inhibitor (17,68). The results of our simulation and the crys-
tallographic structure (11) show that Trp252 is positioned in
the center of the membrane, being away from the binding
site. Nevertheless, in both the experimental structure and
the simulation, the aromatic group of Trp252 forms aromatic
nonpolar interactions with CXCR4 residues Phe248, Tyr255,
Tyr256, and Phe192, which can be most important for the
stabilization of the nucleus of aromatic residues and conse-
quently, the hydrogen bond formation between Tyr255 OH
of CXCR4 and Arg18 NH1/2 of the V3 loop. The latter inter-
action should be significant, owing to the experimentally
determined critical role of Tyr255 and Tyr256 (17,18,68).
Our results justify the decrease of activity upon Glu268
substitution to alanine, because Glu268 participates in a
highly interacting salt bridge with V3 loop residue Arg3
(21). Glu288 of CXCR4 is determined to be one of the
most critical residues for HIV-1 coreceptor activity, because
even an aspartic acid substitution at this position, which pre-
serves the physicochemical properties of the former, results
in a considerable 30–60% loss of HIV-1 coreceptor activity
(17,18); also, alanine substitutions on Glu288 resulted in a
significant decrease of coreceptor activity related to
SDF1a, DV1 and the V3 loop (18,68). Within our simula-
tion, Glu288 forms the most highly interacting salt bridge
with Arg18 of the V3 loop. Because Arg18 of the V3 loop
is simultaneously forming two highly interacting salt
bridges with CXCR4 residues Asp171 and Glu288 residues,
our data suggest that a substitution to Asp288 could not
permit Arg18 to form the two concurrent salt bridges due
to the shorter size of aspartate compared to glutamate
(Fig. 2 A). Alanine substitutions at CXCR4 residues
His294 and Asn298 showed that these residues correlate
with HIV-1 coreceptor activity (17,18). Their presence
below the center of the membrane, far from the binding
site, also in the crystallographic structure (11), suggests
that their role should be attributed to their involvement in
intramolecular interactions within CXCR4.CONCLUSIONS
We consider that the success of having remarkable accor-
dancewith experimental results is due to the systematicmeth-
odology employed, which includes the following features:
1. The modeling of the entire CXCR4 structure and the use
of an extensive set of computational tools and methods to
produce a variety of structural templates of V3 loop and
CXCR4 for docking;Biophysical Journal 105(6) 1502–1514
1512 Tamamis and Floudas2. The large number of docked complexes investigated;
3. The heterogeneous dielectric solvation models used to
rank the complex structures according to their binding
free energy;
4. The employment of MD simulations for the most prom-
ising complexes, with regard to their binding free energy,
in order to improve the conformational sampling and in-
teractions; and
5. The selection of the final complex acquiring the lowest
average binding free energy affinity throughout the MD
simulations.
These steps constitute a systematic methodology, and our
study suggests that a similar computational framework can
be applied for the elucidation of subsequent V3
loop:CXCR4/CCR5 complexes, ormore generally, a broader
series of ligand-G protein coupled receptor complexes.
The identification of the most highly interacting V3 loop
and CXCR4 residues, as well as the specificity of interacting
residue pairs accomplished in this study, could provide gate-
ways for the de novo design of novel inhibitors targeting key
CXCR4 residues and serving as antagonists against HIV-1
(70). According to the results of recent experiments and
computational modeling, the novel HIV-1 inhibitor, DV1,
partially meets the above hypothesis as it participates in po-
lar interactions with CXCR4 residues Asp171 and Glu288
(68), the two most highly interacting polar residues identi-
fied in this study. Guided by the findings of the present
study, and within this direction, de novo design methods
(62,71,72) in conjunction with binding free energy calcula-
tions and MD simulations, as in Tamamis et al. (62), can be
implemented to design new peptides acquiring augmented
interactions with the key CXCR4 residues for HIV-1 core-
ceptor activity.
We employed computational methods, predominantly
comprising MD simulations, as well as binding and interac-
tion free energy calculations, to investigate the molecular
recognition of CXCR4 by a dual receptor HIV-1 gp120
V3 loop. The reported complex structure, despite acquiring
absolutely no bias toward experimental results, is in a
remarkable accordance with experiments. To our knowl-
edge, it is the first reported V3 loop:CXCR4 complex struc-
ture to shed light on the functional role of the HIV-1 gp120
V3 loop and chemokine receptor residues, which are exper-
imentally associated with HIV-1 coreceptor activity.SUPPORTING MATERIAL
Supporting Material comprises additional information on Methods for Step
2, Step 3, Step 5, coordinates of structures in Complex 1 (extracted every 2
ns), the definition of CXCR4 and V3 Loop Domains, two figures, four ta-
bles, and a movie are available at http://www.biophysj.org/biophysj/
supplemental/S0006-3495(13)00873-4.
All MD simulations and free energy calculations were performed on SES-
AME and TIGER computer clusters at the TIGRESS high performance
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